DrugPatentWatch Database Preview
AGGRASTAT Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Aggrastat, and when can generic versions of Aggrastat launch?
Aggrastat is a drug marketed by Medicure and is included in two NDAs. There are two patents protecting this drug.
This drug has twelve patent family members in six countries.
The generic ingredient in AGGRASTAT is tirofiban hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tirofiban hydrochloride profile page.
Summary for AGGRASTAT
| International Patents: | 12 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 50 |
| Clinical Trials: | 11 |
| Patent Applications: | 3,712 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AGGRASTAT |
| DailyMed Link: | AGGRASTAT at DailyMed |
Generic Entry Opportunity Date for AGGRASTAT
Generic Entry Dates for AGGRASTAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION |
Generic Entry Dates for AGGRASTAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for AGGRASTAT
| Drug Class | Platelet Aggregation Inhibitor |
| Physiological Effect | Decreased Platelet Aggregation |
Synonyms for AGGRASTAT
| (2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid |
| (2S)-2-(BUTYLSULFONYLAMINO)-3-[4-[4-(4-PIPERIDYL)BUTOXY]PHENYL]PROPANOIC ACID |
| (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid |
| (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid, N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine |
| (S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid |
| 140430-EP2277565A2 |
| 140430-EP2277566A2 |
| 140430-EP2277567A1 |
| 140430-EP2277568A2 |
| 140430-EP2277569A2 |
| 140430-EP2277570A2 |
| 140430-EP2292280A1 |
| 142373-60-2 (hydrochloride) |
| 144494-65-5 |
| 151065-53-1 |
| 494T655 |
| AB1009554 |
| AC1L1U7O |
| AC1Q6VFB |
| AGG |
| Aggrastat (TN) |
| aggrestat |
| Agrastat |
| Agrastat (TN) |
| AKOS015894972 |
| AN-31474 |
| API0005653 |
| AX8154227 |
| BDBM50004058 |
| BIDD:GT0363 |
| C07965 |
| C22H36N2O5S |
| CHEBI:9605 |
| CHEMBL916 |
| COKMIXFXJJXBQG-NRFANRHFSA-N |
| CS-2829 |
| D08607 |
| D0BN9X |
| DB00775 |
| DR002726 |
| DTXSID20162730 |
| EBD44261 |
| FT-0773940 |
| GGX234SI5H |
| GTPL6586 |
| HSDB 7323 |
| HY-17369B |
| J-524973 |
| KB-269052 |
| KS-00000H6G |
| L-700,462 |
| L-700462 |
| L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)- |
| L700462;MK383 |
| LS-173214 |
| MFCD05237246 |
| MK-383 |
| MolPort-006-167-632 |
| N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine |
| N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine |
| N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE |
| n-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine |
| N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)-butyl)-(s)-tyrosine |
| RL01804 |
| s3085 |
| SC-96683 |
| SCHEMBL3685 |
| tirofiban |
| Tirofiban (INN) |
| Tirofiban [BAN:INN] |
| Tirofiban [INN:BAN] |
| Tirofiban HCl |
| TIROFIBAN HYDROCHLORIDE |
| tirofiban hydrochloride (monohydrate) |
| Tirofiban, >=98.5% (HPLC) |
| Tirofiban[BAN:INN] |
| tirofibanum |
| UNII-GGX234SI5H |
| ZINC3806104 |
US Patents and Regulatory Information for AGGRASTAT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-002 | May 17, 2002 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-001 | May 14, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912-001 | May 14, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-001 | May 14, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-002 | May 17, 2002 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912-001 | May 14, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for AGGRASTAT
see a sample report or, see our see our flat-rate plans
International Patents for AGGRASTAT
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2005532306 | ➤ Try a Free Trial |
| Canada | 2318215 | ➤ Try a Free Trial |
| Australia | 740941 | ➤ Try a Free Trial |
| Japan | 2002501936 | ➤ Try a Free Trial |
| Australia | 2350699 | ➤ Try a Free Trial |
| European Patent Office | 1068172 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for AGGRASTAT
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB99/042 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: TIROFIBAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE HYDROCHLORIDE; REGISTERED: LI 54761 19980528; CH 54761 19980528; DE 42618.00.00 19980630; DE 42618.00.01 19980630; DE 42620.00.00 19980630; DE 42620.00.01 19980630; UK PL 00025/0375 19990715; UK PL 00025/0376 19990715 |
| 00C/002 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: TIROFIBANUM HYDROCHLORIDUM (EQ. TIROFIBAN); NAT. REGISTRATION NO/DATE: 922 IS 191 F 12 19990906; FIRST REGISTRATION: CH 54761 19980528 |
| /1999 | Austria | ➤ Try a Free Trial | PRODUCT NAME: TIROFIBAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-23140 UND 1-23141 19990714; FIRST REGISTRATION: LI IKS-NR 54761 19980528 |
| 90040 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: TIROFIBAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN HYDRAAT, IN HET BIJZONDER TIROFIBANHY- DROCHLORIDE MONOHYDRAAT; NATL REGISTRATION NO/DATE: RVG 23380-1 19990707; FIRST REGISTRATION: DE 42618.00.00-01 19980630 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
